晚发型类风湿关节炎患者功能结局不良及不利临床事件风险更高:IORRA队列研究结果
基于IORRA队列2000至2016年诊断的早期RA患者,比较晚发型(≥65岁,n=813)与年轻型(<65岁,n=2457)患者5年结局。两组疾病活动度改善相似,但晚发型患者躯体功能进行性恶化,且死亡和恶性肿瘤发生率更高。
要点
- 晚发型RA与年轻型RA在5年内疾病活动度改善程度相似。
- 晚发型RA患者J-HAQ评分在第2年后进行性恶化,第5年均值0.56,高于年轻型0.33。
- 晚发型RA患者不良事件发生率更高,死亡校正风险比4.70,恶性肿瘤校正风险比2.58。
核心结论
- 晚发型与年轻型RA患者5年内疾病活动度改善相似,但晚发型患者躯体功能下降更明显。
研究设计与样本
- 分析IORRA队列中2000至2016年诊断的早期RA(病程<2年)患者,分为晚发型(≥65岁,n=813,中位年龄71岁)和年轻型(<65岁,n=2457,中位年龄51岁)。
- 主要结局为第5年CDAI和J-HAQ变化,次要结局为预设不良事件发生率。
主要发现
- 甲氨蝶呤、生物制剂改善病情抗风湿药和糖皮质激素使用率在晚发型组分别为70.6%、8.4%和38.0%,年轻型组分别为81.6%、19.4%和32.0%。
- 两组CDAI和J-HAQ评分初期均显著改善。
- 第5年CDAI均值晚发型组4.39,年轻型组4.03。
- 年轻型组J-HAQ评分第2年后稳定在0.5以下,晚发型组进行性恶化;第5年J-HAQ均值晚发型组0.56,年轻型组0.33。
- 晚发型组不良事件发生率更高,死亡校正风险比4.70,恶性肿瘤校正风险比2.58。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare treatment outcomes in patients with late-onset RA (LORA) and younger-onset RA (YORA). METHODS: We analyzed patients diagnosed with early RA (disease duration < 2 years) between 2000 and 2016 in the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) cohort. Patients were categorized into LORA (onset at ≥65 years) and YORA (onset at <65 years). The primary outcomes were changes in Clinical Disease Activity Index (CDAI) and Japanese version of the Health Assessment Questionnaire (J-HAQ) at Year 5. The secondary outcomes included the incidence of prespecified adverse events. RESULTS: Methotrexate, biological disease-modifying anti-rheumatic drugs, and glucocorticoids were used in 70.6, 8.4 and 38.0% of the LORA group (n = 813, median age: 71 years), and 81.6, 19.4 and 32.0% of the YORA group (n = 2457, median age: 51 years). Both groups exhibited significant initial improvements in CDAI and J-HAQ scores. At Year 5, mean CDAI scores were 4.39 and 4.03 for the LORA and YORA groups, respectively. J-HAQ score for YORA remained stable below 0.5 after Year 2, whereas that for LORA worsened progressively. At Year 5, mean J-HAQ scores were 0.56 for LORA and 0.33 for YORA. Patients with LORA had a higher incidence of adverse events, with adjusted hazard ratios of 4.70 for death and 2.58 for malignancy. CONCLUSIONS: Patients with LORA and YORA exhibited similar improvements in disease activity over 5 years; however, those with LORA demonstrated a more pronounced decline in physical function.
引用
- Sugitani N, Tanaka E, Inoue E, et al. Higher risk of poor functional outcome and unfavourable clinical events for late-onset rheumatoid arthritis: results from the IORRA cohort. Rheumatology (Oxford). 2025. PMID: 39680892. doi:10.1093/rheumatology/keae673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。